Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: A cohort study

Schizophrenia Research

Volumn 111, Issue 1-3, 2009, Pages 1-8

  Bai, Ya Mei ^a,b   Chen, Tzu Ting ^c   Yang, Wei Shiung ^d   Chi, Yu Chao ^d   Lin, Chao Cheng ^d,e   Liou, Ying Jay ^a   Wang, Ying Chieh ^c   Su, Tung Ping ^a,b   Chou, Pesus ^b   Chen, Jen Yeu ^c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c YULI VETERANS HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adiponectin; Antipsychotic agents; Metabolic syndrome

Indexed keywords

ADIPONECTIN; CLOZAPINE; OLANZAPINE; RISPERIDONE;

ADULT; AGE DISTRIBUTION; ANTHROPOMETRY; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC PARAMETERS; METABOLIC SYNDROME X; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT DURATION;

ADIPONECTIN; ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METABOLIC DISEASES; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TAIWAN;

EID: 67349244019     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.03.014     Document Type: Article

References (27)

1. 2004. Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry. 65, 267-272.
2. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., Hotta K., Shimomura I., Nakamura T., Miyaoka K., Kuriyama H., Nishida M., Yamashita S., Okubo K., Matsubara K., Muraguchi M., Ohmoto Y., Funahashi T., and Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257 (1999) 79-83
3. Bai Y.M., Chen J.Y., Yang W.S., Chi Y.C., Liou Y.J., Lin C.C., Wang Y.C., Lin C.Y., Su T.P., and Chou P. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. J. Clin. Psychiatry 68 (2007) 1834-1839
4. Choi K.M., Lee J., Lee K.W., Seo J.A., Oh J.H., Kim S.G., Kim N.H., Choi D.S., and Baik S.H. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin. Endocrinol. (Oxf.) 61 (2004) 75-80
5. Chuang S.Y., Chen C.H., and Chou P. Prevalence of metabolic syndrome in a large health check-up population in Taiwan. J. Chin. Med. Assoc. 67 (2004) 611-620
6. Cohn T., Prud'homme D., Streiner D., Kameh H., and Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can. J. Psychiatry 49 (2004) 753-760
7. De Hert M.A., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., and Peuskens J. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr. Res. 83 (2006) 87-93
8. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
9. Gordon M.E., and McKeever K.H. Diurnal variation of ghrelin, leptin, and adiponectin in Standardbred mares. J. Anim. Sci. 83 (2005) 2365-2371
10. Hanssens L., van Winkel R., Wampers M., Van Eyck D., Scheen A., Reginster J.Y., Collette J., Peuskens J., and De Hert M. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr. Res. (2008)
11. Henderson D.C. Schizophrenia and comorbid metabolic disorders. J. Clin. Psychiatry 66 Suppl 6 (2005) 11-20
12. Hennekens C.H., Hennekens A.R., Hollar D., and Casey D.E. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 150 (2005) 1115-1121
13. Hosojima H., Togo T., Odawara T., Hasegawa K., Miura S., Kato Y., Kanai A., Kase A., Uchikado H., and Hirayasu Y. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J. Psychopharmacol. 20 (2006) 75-79
14. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., Taskinen M.R., and Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
15. Jin H., Meyer J.M., Mudaliar S., and Jeste D.V. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr. Res. 100 (2008) 70-85
16. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Scott S.T., and Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80 (2005) 19-32
17. Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk. J. Clin. Psychiatry 68 Suppl 4 (2007) 8-13
18. Newcomer J.W. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J. Clin. Psychiatry 68 Suppl 1 (2007) 20-27
19. Patel A., Huang K.C., Janus E.D., Gill T., Neal B., Suriyawongpaisal P., Wong E., Woodward M., and Stolk R.P. Is a single definition of the metabolic syndrome appropriate?-A comparative study of the USA and Asia. Atherosclerosis 184 (2006) 225-232
20. Richards A.A., Hickman I.J., Wang A.Y., Jones A.L., Newell F., Mowry B.J., Whitehead J.P., Prins J.B., and Macdonald G.A. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. J. Clin. Psychopharmacol. 26 (2006) 232-237
21. Shand B., Elder P., Scott R., Frampton C., and Willis J. Biovariability of plasma adiponectin. Clin. Chem. Lab. Med. 44 (2006) 1264-1268
22. Sporn A.L., Bobb A.J., Gogtay N., Stevens H., Greenstein D.K., Clasen L.S., Tossell J.W., Nugent T., Gochman P.A., Sharp W.S., Mattai A., Lenane M.C., Yanovski J.A., and Rapoport J.L. Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study. J. Am. Acad. Child Adolesc. Psychiatry 44 (2005) 925-933
23. Togo T., Kojima K., Shoji M., Kase A., Uchikado H., Katsuse O., Iseki E., and Kosaka K. Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study. Int. Clin. Psychopharmacol. 19 (2004) 37-40
24. Trujillo M.E., and Scherer P.E. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J. Intern. Med. 257 (2005) 167-175
25. Valle M., Martos R., Gascon F., Canete R., Zafra M.A., and Morales R. Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome. Diabetes Metab. 31 (2005) 55-62
26. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Reitman M.L., Kagechika H., Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., and Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7 (2001) 941-946
27. Yildiz B.O., Suchard M.A., Wong M.L., McCann S.M., and Licinio J. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10434-10439